Group 1 - Novo Nordisk's Wegovy shows significant advantages in reducing the risk of severe cardiovascular events, with a 57% reduction in risk compared to Eli Lilly's Zepbound [1] - The STEER study, based on data from over 20,000 cardiovascular disease patients aged 45 and above, confirms the cardiovascular benefits of GLP-1 drugs for non-diabetic obese patients [1] - The average follow-up period for the Wegovy group was 8.3 months, while the Zepbound group had 8.6 months, indicating sustained effects of the drugs in real-world applications [1] Group 2 - Wegovy is approved in the US and EU not only for obesity treatment but also for reducing the risk of major cardiovascular events in overweight or obese adults with cardiovascular disease [2] - The study data may further solidify Wegovy's leading position in the GLP-1 weight loss drug market and provide new treatment options for millions of obese patients with cardiovascular disease globally [2]